Date Title
6 Dec Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016
30 Nov Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016
14 Nov Redx Pharma in the running for prestigious North of England awards
10 Nov Redx backs global AMR event
4 Nov Redx to present pre-clinical profile of its reversible BTK inhibitor at ASH 2016
20 Oct Development candidate chosen for leukaemia program
27 Sep Discovery of breakthrough antibiotic compounds
19 Sep Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy
8 Sep Board and Senior Management Changes
6 Sep Supply contract agreed with Quay Pharma for expected clinical trial of Porcupine inhibitor
17 Jun Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference
10 Jun Redx backs North of England biotech focus
6 Jun World leaders in biotech to hear from Northern Powerhouse
24 May Proof of concept with key oncology lead
24 May Interim Results
19 May O'Neill signs off with powerful plan to tackle superbugs
13 May Redx supports young scientists in Staffordshire University’s GradEX exhibition
9 May Board appointment
16 Apr Redx Pharma to present at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans on 20 April
14 Apr Redx Pharma Plc set for new HQ at Alderley Park
12 Apr Redx backs key AMR conference
24 Mar Placing to Raise £10 Million
26 Feb Redx honoured at Institute of Directors Awards
24 Feb AGM Statement - Sixth proof of concept - Potential new treatment for gonorrhoea
3 Feb World Cancer Day 2016
21 Jan Redx joins global pharma call on governments to help tackle AMR crisis
20 Jan Final Results for the year ended 30 September 2015
1 Jan Appointment of Non-Executive Director

2015 news

Filter Options

  • Show All
  • Show only:
  • Redx Pharma
  • Redx Anti-Infectives
  • Redx Immunology
  • Redx Oncology